Compare AbCellera Biologics Inc (ABCL) vs Kohl's Corporation (KSS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Kohl's Corporation — how do they compare? AbCellera Biologics Inc trades at $7.11 (market cap $2.35B), while Kohl's Corporation trades at $16 (market cap $1.90B). The key difference: AbCellera Biologics Inc is the larger of the two by market cap, and Kohl's Corporation pays a 2.98% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | KSS | |
|---|---|---|
Market Cap | $2.35B | $1.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $24.71 |
52-Week Low | $2.78 | $9.08 |
Enterprise Value | $1.99B | $8.00B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Kohl's (KSS) trades at $16.76, down 7.86% on the day, with the stock showing mixed technical signals amid a broader turnaround effort. The company demonstrates improving fundamentals with recent earnings beats and proprietary brand growth, though revenue continues to decline. Valuation metrics appear attractive with a P/E of 7.1 and P/S of 0.12, while technical indicators show bullish moving averages but neutral oscillators.
Kohl's presents a compelling value opportunity with strong proprietary brand momentum and cost controls, though execution risks remain high amid declining sales and intense retail competition. The stock's current price aligns with analyst consensus targets, suggesting limited near-term upside without clearer evidence of sustainable revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
